BioMarin Pharmaceutical (NASDAQ:BMRN) : The consensus on BioMarin Pharmaceutical (NASDAQ:BMRN) based on 16 analyst recommendation on the company stock is 1.38, which is interpreted as a Strong Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 12 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 2 analyst believes that the stock is a Buy, which can produce decent returns in the future. 2 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
BioMarin Pharmaceutical (NASDAQ:BMRN) has been rated by 15 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $150 and the lowest price target forecast is $99. The average forecast of all the analysts is $111.33 and the expected standard deviation is $12.48.
For the current week, the company shares have a recommendation consensus of Buy. Also, BMO Capital initiates coverage on BioMarin Pharmaceutical (NASDAQ:BMRN). The current rating of the shares is Outperform, according to the research report released by the firm. The rating by the firm was issued on April 7, 2016.
BioMarin Pharmaceutical (NASDAQ:BMRN): stock turned positive on Tuesday. Though the stock opened at $76.23, the bulls momentum made the stock top out at $79.71 level for the day. The stock recorded a low of $76.02 and closed the trading day at $79.49, in the green by 6.54%. The total traded volume for the day was 1,585,069. The stock had closed at $74.61 in the previous days trading.
In an insider trading activity, The director, of Biomarin Pharmaceutical Inc, Lawlis V Bryan had unloaded 550 shares at $82.77 per share in a transaction on June 20, 2016. The total value of transaction was $45,524. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).